Home > Insider Trading > Filing (0001062993-21-005353)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1742927	Reviva Pharmaceuticals Holdings Inc.	RVPH	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1015823	Parag Saxena	C/O Vedanta Management Lp 250 West 55Th Street, Suite 13D New York NY 10019	Yes	No	Yes	No
1502216	Vedanta Partners, Llc	C/O Vedanta Management Lp 250 West 55Th Street, Suite 13D New York NY 10019	No	No	Yes	No
1502222	Vedanta Associates, L.p.	C/O Vedanta Management Lp 250 West 55Th Street, Suite 13D New York NY 10019	No	No	Yes	No
1614642	Beta Operators Fund, L.p.	C/O Vedanta Management Lp 250 West 55Th Street, Suite 13D New York NY 10019	No	No	Yes	No
1865703	Vedanta Associates-R, Lp	C/O Vedanta Management Lp 250 West 55Th Street, Suite 13D New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-01	931,000	$3.75	931,000	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2021-06-01	399,000	$3.75	399,000	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants (right to buy)	Acquisiton	2021-06-01	931,000	$0.00	698,250	$4.13
Common Stock	Warrants (right to buy)	Acquisiton	2021-06-01	399,000	$0.00	299,250	$4.13

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
931,000	2021-06-01	2026-06-01	No	4	P	Indirect
399,000	2021-06-01	2026-06-01	No	4	P	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	99,539	Indirect	See Footnotes
Common Stock	871,337	Indirect	See Footnote

Footnotes

The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share.
Held directly by Vedanta Associates-R, L.P. ("Vedanta Associates-R"). Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners.
Held directly by Beta Operators Fund, L.P. ("Beta Operators Fund"). Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners.
Held directly by Vedanta Associates. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners.
Held directly by Mr. Saxena.
Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein.
Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein.